Efficacy and safety of SOBERANA 02, a COVID-19 conjugate vaccine in heterologous three-dose combination
View ORCID ProfileM. Eugenia Toledo-Romani, M. Garcia-Carmenate, View ORCID ProfileC. Valenzuela Silva, W. Baldoquin-Rodriguez, M. Martínez Pérez, View ORCID ProfileM. C. Rodríguez Gonzalez, B. Paredes Moreno, I. C. Mendoza Hernández, R. González-Mujica Romero, O. Samón Tabio, P. M. Velazco Villares, J. P. Bacallao Castillo, E. Licea Martín, M. Rodríguez Ortega, View ORCID ProfileN. L. Herrera Marrero, View ORCID ProfileE. Caballero Gonzalez, L. I. Egües Torres, R. Duarte González, S. García Blanco, S. Pérez Cabrera, S. Huete Ferreira, K. Idalmis Cisnero, O. Fonte Galindo, D. Meliá Pérez, I. Rojas Remedios, S. Fernandez Castillo, View ORCID ProfileY. Climent Ruiz, Y. Valdes-Balbin, View ORCID ProfileD. Garcia-Rivera, View ORCID ProfileV. Verez Bencomo, the SOBERANA Phase 3 team
doi: https://doi.org/10.1101/2021.10.31.21265703
M. Eugenia Toledo-Romani
2Pedro Kourí Tropical Medicine Institute, Havana
M. Garcia-Carmenate
3Havana Province Hygiene and Epidemiology Center
C. Valenzuela Silva
4Cybernetics, Mathematics and Physics Institute, Havana
W. Baldoquin-Rodriguez
2Pedro Kourí Tropical Medicine Institute, Havana
M. Martínez Pérez
1Finlay Vaccine Institute, Havana
M. C. Rodríguez Gonzalez
1Finlay Vaccine Institute, Havana
B. Paredes Moreno
1Finlay Vaccine Institute, Havana
I. C. Mendoza Hernández
5National Clinical Trials Coordinating Center, Havana
R. González-Mujica Romero
1Finlay Vaccine Institute, Havana
O. Samón Tabio
6José Antonio Echevarría Technological University, Havana
P. M. Velazco Villares
7UCT Geocuba Research and Consulting, Havana
J. P. Bacallao Castillo
7UCT Geocuba Research and Consulting, Havana
E. Licea Martín
1Finlay Vaccine Institute, Havana
M. Rodríguez Ortega
2Pedro Kourí Tropical Medicine Institute, Havana
N. L. Herrera Marrero
2Pedro Kourí Tropical Medicine Institute, Havana
E. Caballero Gonzalez
1Finlay Vaccine Institute, Havana
L. I. Egües Torres
3Havana Province Hygiene and Epidemiology Center
R. Duarte González
3Havana Province Hygiene and Epidemiology Center
S. García Blanco
3Havana Province Hygiene and Epidemiology Center
S. Pérez Cabrera
3Havana Province Hygiene and Epidemiology Center
S. Huete Ferreira
3Havana Province Hygiene and Epidemiology Center
K. Idalmis Cisnero
3Havana Province Hygiene and Epidemiology Center
O. Fonte Galindo
3Havana Province Hygiene and Epidemiology Center
D. Meliá Pérez
3Havana Province Hygiene and Epidemiology Center
I. Rojas Remedios
3Havana Province Hygiene and Epidemiology Center
S. Fernandez Castillo
1Finlay Vaccine Institute, Havana
Y. Climent Ruiz
1Finlay Vaccine Institute, Havana
Y. Valdes-Balbin
1Finlay Vaccine Institute, Havana
D. Garcia-Rivera
1Finlay Vaccine Institute, Havana
V. Verez Bencomo
1Finlay Vaccine Institute, Havana
![Loading Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif)
Article usage
Posted November 06, 2021.
Efficacy and safety of SOBERANA 02, a COVID-19 conjugate vaccine in heterologous three-dose combination
M. Eugenia Toledo-Romani, M. Garcia-Carmenate, C. Valenzuela Silva, W. Baldoquin-Rodriguez, M. Martínez Pérez, M. C. Rodríguez Gonzalez, B. Paredes Moreno, I. C. Mendoza Hernández, R. González-Mujica Romero, O. Samón Tabio, P. M. Velazco Villares, J. P. Bacallao Castillo, E. Licea Martín, M. Rodríguez Ortega, N. L. Herrera Marrero, E. Caballero Gonzalez, L. I. Egües Torres, R. Duarte González, S. García Blanco, S. Pérez Cabrera, S. Huete Ferreira, K. Idalmis Cisnero, O. Fonte Galindo, D. Meliá Pérez, I. Rojas Remedios, S. Fernandez Castillo, Y. Climent Ruiz, Y. Valdes-Balbin, D. Garcia-Rivera, V. Verez Bencomo, the SOBERANA Phase 3 team
medRxiv 2021.10.31.21265703; doi: https://doi.org/10.1101/2021.10.31.21265703
Efficacy and safety of SOBERANA 02, a COVID-19 conjugate vaccine in heterologous three-dose combination
M. Eugenia Toledo-Romani, M. Garcia-Carmenate, C. Valenzuela Silva, W. Baldoquin-Rodriguez, M. Martínez Pérez, M. C. Rodríguez Gonzalez, B. Paredes Moreno, I. C. Mendoza Hernández, R. González-Mujica Romero, O. Samón Tabio, P. M. Velazco Villares, J. P. Bacallao Castillo, E. Licea Martín, M. Rodríguez Ortega, N. L. Herrera Marrero, E. Caballero Gonzalez, L. I. Egües Torres, R. Duarte González, S. García Blanco, S. Pérez Cabrera, S. Huete Ferreira, K. Idalmis Cisnero, O. Fonte Galindo, D. Meliá Pérez, I. Rojas Remedios, S. Fernandez Castillo, Y. Climent Ruiz, Y. Valdes-Balbin, D. Garcia-Rivera, V. Verez Bencomo, the SOBERANA Phase 3 team
medRxiv 2021.10.31.21265703; doi: https://doi.org/10.1101/2021.10.31.21265703
Subject Area
Subject Areas
- Addiction Medicine (349)
- Allergy and Immunology (671)
- Anesthesia (181)
- Cardiovascular Medicine (2661)
- Dermatology (224)
- Emergency Medicine (402)
- Epidemiology (12264)
- Forensic Medicine (10)
- Gastroenterology (765)
- Genetic and Genomic Medicine (4122)
- Geriatric Medicine (387)
- Health Economics (681)
- Health Informatics (2670)
- Health Policy (1008)
- Hematology (364)
- HIV/AIDS (855)
- Medical Education (399)
- Medical Ethics (109)
- Nephrology (442)
- Neurology (3912)
- Nursing (210)
- Nutrition (582)
- Oncology (2048)
- Ophthalmology (587)
- Orthopedics (242)
- Otolaryngology (306)
- Pain Medicine (250)
- Palliative Medicine (75)
- Pathology (473)
- Pediatrics (1116)
- Primary Care Research (455)
- Public and Global Health (6551)
- Radiology and Imaging (1410)
- Respiratory Medicine (872)
- Rheumatology (412)
- Sports Medicine (344)
- Surgery (452)
- Toxicology (54)
- Transplantation (186)
- Urology (167)